Should divalproex 250 mg delayed‑release tablets be prescribed for a patient with Parkinson’s disease?

Divalproex Should Generally Be Avoided in Patients with Parkinson's Disease

Divalproex (valproate) can cause or worsen parkinsonism and should not be routinely prescribed for patients with Parkinson's disease. While the FDA-approved indications for divalproex include epilepsy, bipolar disorder, and migraine prophylaxis 1, there is substantial evidence that valproate can induce parkinsonian symptoms that may be difficult to distinguish from idiopathic Parkinson's disease.

Key Evidence Against Use in Parkinson's Disease

Drug-Induced Parkinsonism Risk

Multiple case series demonstrate that valproic acid can cause a reversible form of parkinsonism characterized by bradykinesia, rigidity, postural instability, and resting tremor 2. This adverse effect is particularly concerning in elderly patients, where:

• The time interval for developing parkinsonism after starting VPA is variable (ranging from months to over 8 years) 3, 4
• Symptoms can be insidious and delayed, making the relationship to the medication initially unclear 2
• The condition may be misdiagnosed as worsening of underlying Parkinson's disease or new-onset idiopathic parkinsonism 2, 3

Clinical Characteristics of VPA-Induced Parkinsonism

The parkinsonian symptoms from valproate can look identical to idiopathic Parkinson's disease 2. Importantly:

• Some patients show levodopa responsiveness, which paradoxically adds to diagnostic confusion 2
• Drug-induced dyskinesia has been observed in VPA-induced parkinsonism patients treated with levodopa 2
• Improvement occurs after discontinuation but may take days to months 2, 4
• The rate and extent of improvement is unpredictable 4

Lack of Therapeutic Benefit

Historical research attempted to use sodium valproate to treat Parkinson's disease based on theories about GABA metabolism, but this approach failed 5. In eight parkinsonian patients:

• Valproate did not significantly improve any parkinsonian features 5
• It tended to increase dyskinesia in patients with "on-off" fluctuations 5
• No consistent alteration of CSF GABA levels could be demonstrated 5

Clinical Decision Algorithm

If a Patient with Parkinson's Disease Requires Treatment for Conditions Where Divalproex Might Be Considered:

For Migraine Prophylaxis:

• Consider alternative first-line agents: propranolol (80-240 mg/day), timolol (20-30 mg/day), or amitriptyline (30-150 mg/day) 6
• Avoid divalproex given the risk of worsening motor symptoms

For Neuropathic Pain:

• Use gabapentin or pregabalin as first-line calcium channel α-δ ligands 7
• Consider duloxetine or venlafaxine as alternatives 7
• While sodium valproate is "probably effective" for painful diabetic neuropathy 8, the risk-benefit ratio is unfavorable in Parkinson's patients

For Bipolar Disorder or Seizures:

• Carefully weigh the necessity of valproate against alternatives
• If absolutely required, use the lowest effective dose
• Monitor closely for emergence or worsening of parkinsonian symptoms
• Establish baseline motor function assessment before initiating therapy

Critical Monitoring Points

If valproate must be used despite Parkinson's disease:

1. Document baseline motor status using standardized scales before starting therapy
2. Monitor for new or worsening parkinsonian symptoms at each visit, particularly:
   • Bradykinesia
   • Rigidity
   • Postural instability
   • Tremor (beyond typical valproate-induced postural tremor)
3. Be aware that onset can be delayed by months to years 3, 4
4. Consider VPA-induced parkinsonism if motor symptoms worsen despite stable dopaminergic therapy
5. Discontinue valproate promptly if drug-induced parkinsonism is suspected, as symptoms are reversible 2, 3

Common Pitfalls to Avoid

• Do not assume worsening motor symptoms represent disease progression without considering medication effects 2, 3
• Do not be falsely reassured by levodopa responsiveness, as VPA-induced parkinsonism can respond to dopaminergic therapy 2
• Do not overlook the diagnosis in patients on long-term valproate, as onset can occur after many years of stable therapy 3
• Do not confuse valproate-induced postural/action tremor with the parkinsonian features of bradykinesia, rigidity, and resting tremor 2